NCT06473246View on ClinicalTrials.gov

A Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

October 5, 2025

Study Completion Date

October 5, 2025

Conditions
Healthy Population
Interventions
DIETARY_SUPPLEMENT

CBD Isolate (25 mg/0.5 ml)

0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.

DIETARY_SUPPLEMENT

CBD Isolate (40 mg/0.5 ml)

0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.

DIETARY_SUPPLEMENT

CBD Isolate (50 mg/0.5 ml)

0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.

DIETARY_SUPPLEMENT

CBD Broad Extract (50 mg/0.5 ml)

0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.

DIETARY_SUPPLEMENT

Placebo

0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.

Trial Locations (6)

411011

RECRUITING

Dhanwantri Hospital, Pune

411019

RECRUITING

Vedant Multispeciality Hospital, Pune

411033

RECRUITING

Punawale Hospital, Pune

412201

RECRUITING

Vishwaraj Hospital, Pune

421201

RECRUITING

Shree Ashirwad Hospital, Thāne

421203

RECRUITING

Shivam Hospital, Dombivali

All Listed Sponsors
lead

Vedic Lifesciences Pvt. Ltd.

INDUSTRY